The effect of obesity pharmacotherapy on body composition, including muscle mass
The DOI matches its Crossref record; 67 of the 68 references it cites were found in a registry or an index.
Abstract
Obesity pharmacotherapy represents a promising approach to treating obesity and may provide benefits beyond weight loss alone. Maintaining or even increasing muscle mass during weight loss is important to overall health, metabolic function and weight loss maintenance. Drugs such as liraglutide, semaglutide, tirzepatide, and naltrexone/bupropion have shown significant weight loss effects, and emerging evidence suggests they may also have effects on body composition, particularly a positive influence on muscle mass. However, further research is needed to fully understand the mechanism of action of these drugs and their effects on muscle mass. Clinicians should consider these factors when developing an obesity treatment plan for an individual patient.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, a more recent review evaluating the effects of obesity pharmacotherapy (including newer incretin-memetics) on body composition concludes that a non-significant percentage of muscle mass is lost, relative to fat mass (11).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [11]
In the citing paper
“Despite the efficacy of GLP‐1 receptor agonists in reducing body weight, limited data exist on their impact on body composition, including changes in fat mass, lean mass, muscle function, and the potential development of sarcopenia defined by a loss of muscle mass and function. 7”
From Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study (2026) · cites this paper as [7]
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 3×
“Additionally, STEP 5 demonstrated that signi fi cant WL observed during 68 weeks of semaglutide treatment could be sustained with continued treatment for at least 104 weeks [41, 44].”
InfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 3×
“DUAL GLP-1/GIP RECEPTOR AGONISTS Tirzepatide is a once-weekly subcutaneous injectable medication, a dual agonist at both the GIP and GLP-1 receptors approved for both T2DM and obesity (FDA) that has recently entered the obesity pharmacotherapy fi eld [58, 59].”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Davies, M. J., Bergenstal, R., Bode, B., Kushner, R. F., Lewin, A., Skjøth, T. V., Andreasen, A. H., Jensen, C. B., DeFronzo, R. A., & for the NN8022-1922 Study Group (2015) · JAMA · doi:10.1001/jama.2015.9676 · Cited by 1,198
Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60888-4 · Cited by 1,036
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868
Aronne, L. J., Sattar, N., Horn, D. B., Bays, H. E., Wharton, S., Lin, W.-Y., Ahmad, N. N., Zhang, S., Liao, R., Bunck, M. C., et al. (2024) · JAMA · doi:10.1001/jama.2023.24945 · Cited by 860 · cited 1×
“A signi fi cant reduction of WC was also seen in the SURMOUNT-4 trial, depicting a probable favorable effect in abdominal fat, a fi nding rather consistent in WL studies [63].”
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850 · cited 1×
“Concurrently, signi fi cant reductions in WC were observed ( − 4.7 cm in the intervention group vs. − 1.2 cm in the placebo group), highlighting liraglutide ’ s impact on abdominal fat [22, 23, 34, 35].”
Influentialon behalf of the NN8022-1923 Investigators, Wadden, T. A., Hollander, P., Klein, S., Niswender, K., Woo, V, Hale, P. M., & Aronne, L. (2013) · International Journal of Obesity · doi:10.1038/ijo.2013.120 · Cited by 842
Research works printed but not linked: 2
- Konwar M, Bose D, Jaiswal SK, Maurya MK, Ravi R. Efficacy and safety of liraglutide 3.0 mg in patients with overweight and obese with or without diabetes: a systematic review and meta-analysis. Int J Clin Pr. 2022;2022:1201977.
- Keskin L, Yaprak B. Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus. Eur Rev Med Pharm Sci. 2022;26:6813–20.
Cited by
Alissou, M., Demangeat, T., Folope, V., Van Elslande, H., Lelandais, H., Blanchemaison, J., Cailleaux, P., Guney, S., Aupetit, A., Aubourg, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70141 · Cited by 72
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70059 · Cited by 56
Beavers, K. M., Cortes, T. M., Foy, C. M., Dinkla, L., Reyes San Martin, F., Ard, J. D., Serra, M. C., & Beavers, D. P. (2025) · Obesity · doi:10.1002/oby.24172 · Cited by 41
Physiology of Weight Regain after Weight Loss: Latest Insights
van Baak, M. A., & Mariman, E. C. M. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00619-x · Cited by 38
Chao, C., Kovesdy, C. P., & Merchant, R. A. (2025) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.24.207 · Cited by 37
Metadata
- Authors
- Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A.
- Affiliations
- Athens Medical Center (GR)
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Argyrakopoulou, Georgia
- Venue
- International Journal of Obesity
- Published
- 2024-05-14
- Volume
- 49
- Issue
- 3
- Pages
- 381-387
- ISSN
- 0307-0565 (ISSN-L)
- 1476-5497
- OpenAlex
- W4396904658
- Cited by
- 28
- References
- 68
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 2
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- International Journal of Obesity (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- obesity pharmacotherapy, body composition, muscle mass, weight loss, liraglutide, semaglutide, tirzepatide, naltrexone/bupropion, weight loss maintenance, GLP-1 receptor agonists, appetite suppressants
- MeSH terms
- Liraglutide, Body Composition, Humans, Naltrexone, Obesity, Weight Loss, Muscle, Skeletal, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of obesity pharmacotherapy on body composition, including muscle mass. https://app.cochat.ai/papers/10.1038/s41366-024-01533-3
- The paper
- Argyrakopoulou, G., Gitsi, E., Konstantinidou, S. K., & Kokkinos, A. (2025). The effect of obesity pharmacotherapy on body composition, including muscle mass. International Journal of Obesity. https://doi.org/10.1038/s41366-024-01533-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.